This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
ThermoGenesis Holdings Beheer
Beheer criteriumcontroles 3/4
We currently do not have sufficient information about the CEO.
Belangrijke informatie
Chris Xu
Algemeen directeur
US$699.0k
Totale compensatie
| Percentage CEO-salaris | 74.2% |
| Dienstverband CEO | 6.9yrs |
| Eigendom CEO | n/a |
| Management gemiddelde ambtstermijn | 6.6yrs |
| Gemiddelde ambtstermijn bestuur | 6.7yrs |
Recente managementupdates
Recent updates
Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2023 | n/a | n/a | -US$14m |
| Mar 31 2023 | n/a | n/a | -US$14m |
| Dec 31 2022 | US$699k | US$519k | -US$11m |
| Sep 30 2022 | n/a | n/a | -US$10m |
| Jun 30 2022 | n/a | n/a | -US$9m |
| Mar 31 2022 | n/a | n/a | -US$11m |
| Dec 31 2021 | US$748k | US$500k | -US$11m |
| Sep 30 2021 | n/a | n/a | -US$12m |
| Jun 30 2021 | n/a | n/a | -US$12m |
| Mar 31 2021 | n/a | n/a | -US$14m |
| Dec 31 2020 | US$2m | US$505k | -US$16m |
| Sep 30 2020 | n/a | n/a | -US$18m |
| Jun 30 2020 | n/a | n/a | -US$17m |
| Mar 31 2020 | n/a | n/a | -US$12m |
| Dec 31 2019 | US$472k | US$472k | -US$9m |
| Sep 30 2019 | n/a | n/a | -US$13m |
| Jun 30 2019 | n/a | n/a | -US$13m |
| Mar 31 2019 | n/a | n/a | -US$39m |
| Dec 31 2018 | US$653k | US$460k | -US$40m |
| Sep 30 2018 | n/a | n/a | -US$32m |
| Jun 30 2018 | n/a | n/a | -US$32m |
| Mar 31 2018 | n/a | n/a | -US$6m |
| Dec 31 2017 | US$1m | US$216k | -US$6m |
Compensatie versus markt: Chris's total compensation ($USD699.00K) is above average for companies of similar size in the German market ($USD417.54K).
Compensatie versus inkomsten: Chris's compensation has been consistent with company performance over the past year.
CEO
Chris Xu (52 yo)
6.9yrs
Tenure
US$699,000
Compensatie
Dr. Xiaochun Xu, also known as Chris, M.B.A. Ph D., is the Founder, Chairman and Chief Executive Officer of Boyalife Group since July 2009.He serves as an Advisor at WI Harper Group. Dr. Xu has been the C...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman of the Board & CEO | 6.9yrs | US$699.00k | geen gegevens | |
| CFO & Corporate Secretary | 6.6yrs | US$325.00k | 0.00064% $ 21.6 | |
| COO & Director | 5.8yrs | US$554.00k | 0% $ 0 |
6.6yrs
Gemiddelde duur
52yo
Gemiddelde leeftijd
Ervaren management: THRP's management team is seasoned and experienced (6.6 years average tenure).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman of the Board & CEO | 7.6yrs | US$699.00k | geen gegevens | |
| COO & Director | 1.8yrs | US$554.00k | 0% $ 0 | |
| Independent Director | 6.7yrs | US$54.50k | 0% $ 0 | |
| Member of Clinical & Scientific Advisory Board | 9.4yrs | geen gegevens | geen gegevens | |
| Member of Clinical Advisory Board | 7.6yrs | geen gegevens | geen gegevens | |
| Independent Director | less than a year | US$99.00k | geen gegevens | |
| Independent Director | 6.8yrs | US$56.00k | 0% $ 0 | |
| Independent Director | less than a year | geen gegevens | geen gegevens |
6.7yrs
Gemiddelde duur
57yo
Gemiddelde leeftijd
Ervaren bestuur: THRP's board of directors are considered experienced (6.7 years average tenure).